Published in
American Association for the Advancement of Science, Science Translational Medicine, 596(13), 2021
DOI: 10.1126/scitranslmed.abc0555
Yearbook of Paediatric Endocrinology, 2022
DOI: 10.1530/ey.19.8.10
Links
Tools
The brain penetrant PPARγ agonist leriglitazone restores multiple altered pathways in models of X-linked adrenoleukodystrophy
Journal article published in 2021 by
Rodriguez-Pascau L.,
Laura Rodríguez-Pascau 
,
Anna Vilalta ,
Vilalta A.,
Marc Cerrada,
Cerrada M.,
Traver E.,
Isabelle Weinhofer,
Estefania Traver,
Sonja Forss-Petter,
Forss-Petter S.,
Weinhofer I.,
Jan Bauer ,
Bauer J.,
Stephan Kemp
and other authors.
,
Anna Vilalta ,
Vilalta A.,
Marc Cerrada,
Cerrada M.,
Traver E.,
Isabelle Weinhofer,
Estefania Traver,
Sonja Forss-Petter,
Forss-Petter S.,
Weinhofer I.,
Jan Bauer ,
Bauer J.,
Stephan Kemp
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 
Abstract
Leriglitazone reduces pathologically activated microglia and protects neurons, astrocytes, and oligodendrocytes in experimental models of X-ALD.